Hologic Inc.
Hologic, Inc. Announces Second Quarter 2024 Financial Results and Raises Guidance
Summary
Hologic, Inc. reported financial results for the second quarter of fiscal 2024 on May 2, 2024. The company's revenue for the quarter was $1,017.8 million, a decrease of 0.8% year-over-year, primarily due to lower sales of COVID-19 assays. However, organic revenue grew 5.0% or 4.9% on a constant currency basis, excluding COVID-19. The company raised its full-year revenue and EPS guidance on strong margins. GAAP diluted EPS for the quarter was $0.72, and non-GAAP diluted EPS was $1.03, both exceeding the high end of their guidance ranges. Cash flow from operations remained robust at $292.4 million.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement